Drug Trial Radar · NCT05989542
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
Last checked: Nov 19, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Oct 16, 2023
Primary completion
Sep 30, 2026
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Beijing Pearl Biotechnology Limited Liability CompanyIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are: * If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation * If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation Participants will 1. be given PLB1001 200mg BID,oral. 2. be received hematology and urine and ECG examinations every 14 days (First 3 months) or every 28 days (After 3 months) 3. be received Image examination every 8 weeks(First year) or every 12 weeks(After one year)
Conditions
- Non-small Cell Lung Cancer
Interventions
PLB1001Drug
200mg BID Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate Evaluated by IRCTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.